July 2024

Will initiate a first-in-human Phase 1 clinical trial for INT2104, its first-in-class in vivo targeted gene therapy, creating CAR cells for the treatment of B cell malignancies in 4Q24 PHILADELPHIA, July 9, 2024 /PRNewswire/ — Interius BioTherapeutics, a leading developer of in vivo cell-speci

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: